Dave Fornell, DAIC Editor

Dave Fornell, editor of DAIC Magazine

Blog | Dave Fornell, DAIC Editor | Cath Lab| November 05, 2015

Trends and New Technology at Transcatheter Cardiovascular Therapeutics (TCT)

For the past few years, the focus of the annual Transcatheter Cardiovascular Therapeutics (TCT) meetings has been on structural heart advances, and the traditional focus on percutaneous coronary intervention (PCI) appeared to take a back seat to make way for the flood of data and new transcatheter valve technologies. While valves are still at the forefront, this year the focus again returned to workhorse PCI stents due to new stents in development and advances in bioresorbable technologies. 

Watch the video Editor's Choice of the Most Innovative New Technologies at TCT 2015

The Boston Scientific Synergy stent gained U.S. Food and Drug Administration (FDA) clearance the week before TCT, becoming the first metallic drug-eluting stent (DES) that uses a bioresorbable drug carrier polymer.  The abluminal polymer coating completely dissolves within three months, eliminating long-term issues related to permanent polymers, which can cause vessel irritation leading to in-stent restenosis and late-stent thrombosis. The Synergy’s approval was widely discussed as a key advancement in DES technology. 

The key late-breaker at TCT was the ABSORB III trial, which is the pivotal FDA study for the Abbott Absorb completely bioresorbable DES. The data show the Absorb had outcomes statistically equal to the Abbott Xience V stent, which to date has the best clinical outcomes data for any DES. 

“There were no statistical differences between the devices for target lesion failure or any of its components,” said Dean Kereiakes, M.D., medical director of  The Christ Hospital Heart and Vascular Center, and a lead investigator for ABSORB III. He said the trial was designed to show non-inferiority to Xience at one year, but the stent itself is designed to improve long-term outcomes to avoid the 2-3 percent per year of stent-related issues (strut fracture, in-stent restenosis, late-stent thrombosis). “The real test is in the long run if the Absorb bioresorbable scaffold improves late outcomes when it’s gone compared to a metal platform,” he explained.

Watch video interview with Kereiakes regarding the ABSORB III trial and Synergy stents

Additional positive data was presented on the bioresorbable stents from the late-breaking ABSORB China, ABSORB II and BIOSOLVE II trials.

Advances in transcatheter valves also were among the major advances at  TCT. Continued positive clinical data from both the Medtronic CoreValve and Edwards Lifesciences’ Sapien valves were presented, including information on the new FDA valve-in-valve indication, and data on improved versions of both valves. Numerous sessions focused on new technologies in development or entering trials for transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR) and tricuspid valve replacement (TTVR). Sessions on mitral and tricuspid valves were packed to capacity again this year, as both of these technologies are seen as key paradigm shifts in the standard of care. With the overwhelming success of TAVR, many TCT experts predict transcatheter valve technologies will largely replace open-heart surgical valves and repairs in the coming years. 

Watch video on these and other trends at TCT 2015 with MDBuyLine's Tom Watson

 

Here are links to additional video interviews conducted at TCT 2015:

Drug-Filled Stents as an Alternative to Polymer Drug Carriers at TCT 2015

Lithoplasty as an Alternative to Treat Calcified Lesions at TCT 2015

Eye-tracking For Dose Reduction in the Cath Lab — TCT 2015

New Approaches to Denervation Therapy at TCT 2015

Update on U.S. Transradial Access Adoption With Sunil Rao at TCT 2015

Advances in Interventional Heart Failure Hemodynamic Support — TCT 2015

Advances in Intravascular Imaging at TCT 2015

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Overlay Init